MIRA PHARMACEUTICALS, INC.
For the period ended Jul 6, 2026. Filed Jul 6, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jul 6, 2026 · Filed Jul 6, 2026
Use the contents to explore the available documents and sections.
MIRA$0.57+5.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Key Study Highlights
Key Study Highlights
| ● | Optimized oral formulation demonstrated favorable oral bioavailability following oral administration. |
| ● | Pharmacokinetic profile supports the potential for convenient once-daily oral dosing. |
| ● | Robust brain penetration and substantial liver exposure following oral administration. |
| ● | Reproducible systemic exposure and target tissue distribution across multiple animals. |
| ● | Findings complement previously reported efficacy, behavioral, mechanistic, and pharmacokinetic studies supporting SKNY-1’s differentiated development profile. |
The Company plans to continue evaluating the relationship between tissue exposure, pharmacodynamic activity, and therapeutic efficacy as SKNY-1 advances through additional preclinical development.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.